DesignNarrative review of NMN metabolism, uptake, bioavailability, and human clinical variability
PopulationNo direct participants; underlying evidence included human trials, animal studies, cellular studies, and biochemical research
SampleNot applicable to the review
InterventionNo original intervention; reviewed heterogeneous oral, intravenous, standard, and proposed delivery approaches
EndpointsNAD+ biosynthesis and NMN metabolic pathways; Gut-microbiome deamidation and cellular uptake mechanisms; Human NAD+ metabolite and functional outcomes; Analytical-method and sample-type variability; Delivery, bioavailability, and future clinical-research priorities
What the publication reported
This narrative review argued that NMN’s biological and clinical effects are difficult to interpret because oral metabolism, gut microbiota, uptake pathways, baseline physiology, sample type, and laboratory methods can differ substantially. It summarized inconsistent human-trial findings and called for standardized analytical methods, better-defined populations, and high-quality trials before firm conclusions about efficacy, dosing, or delivery can be made.
Key findings
Orally administered NMN can be substantially transformed by gut microbes and host enzymes before reaching tissues.
The relative contribution of direct NMN transport versus conversion to other precursors remains unresolved.
Human trials have reported inconsistent NAD+ and functional outcomes across populations, doses, and sample types.
Baseline physiology, lifestyle, genetics, health status, and gut microbiome composition may contribute to response variability.
Blood NAD+ is an incomplete proxy for tissue-specific effects, and standardized collection and analytical methods are needed.
What it cannot establish
Narrative review without a prespecified systematic search, meta-analysis, or formal risk-of-bias synthesis.
The underlying evidence is heterogeneous across preclinical and human studies, formulations, routes, doses, and endpoints.
Several delivery and bioavailability arguments are mechanistic, inferential, or based on non-human evidence.
Both authors were employees of Renue By Science, and the company funded the article processing fee.
The review cannot establish an optimal NAD+ threshold, personalized dose, or clinical benefit for a specific product.
HealthspanX claim boundary: This review does not establish personalized NMN dosing, superiority of a delivery system, or clinical benefits for any consumer or product. Its discussion of formulation and bioavailability is interpretive, not a controlled comparison.
